Pharmaceutical Supply Chain Defense and Enhancement Act
Latest action · Jul 2, 2020 Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Progress
Where this bill reached, and when. A stage with no date was not reached; one that failed a vote and later carried shows the date it carried.
- IntroducedJul 2, 2020
- Passed SenateNot reached
- Passed HouseNot reached
- To the PresidentNot reached
- Became lawNot reached
Summary
Pharmaceutical Supply Chain Defense and Enhancement Act
This bill requires the Department of Health and Human Services (HHS) to enter into contracts with U.S. entities to manufacture certain critical drugs within the United States and otherwise addresses drug manufacturing.
HHS must periodically report to Congress a list of drugs that are critical to public health or national security. The Biomedical Advanced Research and Development Authority within HHS must enter into contracts for qualified U.S. entities to manufacture in the United States the drugs on this list (and ingredients for such drugs). The contracts must impose certain conditions, such as those requiring the manufacturing entity to (1) develop and maintain a redundancy risk management and continuity of business plan, and (2) commit to selling the drugs and ingredients manufactured under the contract at reasonable prices.
Beginning in FY2024, certain federal agencies (including the Department of Defense and the Bureau of Prisons) must, in procuring drugs on the HHS critical drugs list, give priority to high-quality drugs that are manufactured in the United States.
This bill also requires the Federal Trade Commission to submit annually to Congress a report on foreign investment in the U.S. pharmaceutical industry. The report must address, among other topics, the effect of the industry's reliance on foreign manufacturing.
Cosponsors 1
Members who signed on, in the order they did. All signed on Jul 2, 2020.
| Seat | Cosponsor | Signed on | |
|---|---|---|---|
| D-MN | Tina Smith | Original | Jul 2, 2020 |
Actions 2
Everything that happened, newest first.
- Jul 2, 2020Introduced in Senate
- Jul 2, 2020Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Related bills 1
Companion bills and other measures the record links to this one.
| Bill | Title | Relationship | Latest action |
|---|---|---|---|
| S 4191 | United States Pharmaceutical Supply Chain Review Act | Related bill | Jul 2, 2020 |
Subjects
Assigned by the Library of Congress. Policy area: Health.
- Congressional oversight
- Drug safety, medical device, and laboratory regulation
- Foreign and international corporations
- Genetics
- Government information and archives
- Government studies and investigations
- Health
- Health care coverage and access
- Health technology, devices, supplies
- Industrial policy and productivity
- Manufacturing
- Prescription drugs
- Public contracts and procurement
- Retail and wholesale trades
- Strategic materials and reserves
- U.S. and foreign investments
- World health
Text 1
Each version as it was printed, newest first.
- Jul 2, 2020Introduced in Senate
Everything here is as published by Congress: the summary is the Congressional Research Service's, the action wording is the clerks', and the subjects are the Library of Congress's. How far it got is read from the actions themselves, taking the most recent one of each kind, so a bill that failed a vote and later passed is shown as having passed. Records come from this bill on Congress.gov and govinfo.gov.